Summary:
Adults with drug-resistant epilepsy who consume recreational cannabis near-daily experience more than twice as many convulsive seizures each year compared to nonusers. A new clinical study also revealed that frequent users progressed to treatment resistance more than three times faster, reaching specialized inpatient care within five years of seizure onset compared to 18 years for nonusers.
Key Facts:
- Double the Convulsive Seizures: Near-daily cannabis users suffered more than double the annual rate of convulsive (tonic-clonic) seizures compared to nonusers, with 90% experiencing these high-risk events versus roughly half of nonusers.
- Rapid Progression to Drug Resistance: Patients using cannabis 20 or more days per month progressed to drug-resistant status and specialized monitoring in an average of 5 years from their first seizure, compared to 18 years in nonusers.
- Absence of Typical Structural Damage: While epilepsy of this severity typically leaves structural scarring on the hippocampus, frequent cannabis users had largely normal structural brain scans, pointing toward functional network disruption driven by cannabinoid receptors rather than overt physical lesions.
Source: Washington University School of Medicine in St. Louis
As recreational cannabis access continues to expand, clinical neurologists have encountered an emerging clinical pattern: young adults presenting with severe, intractable seizures in the absence of traditional neurological risk factors. While public interest in cannabis-based therapeutics remains high, the specific impact of high-potency, frequent recreational cannabis use on the progression of refractory epilepsy has been largely unquantified.
In a retrospective study published in the journal Epilepsia, researchers from the Washington University School of Medicine in St. Louis and the University of Wisconsin School of Medicine and Public Health uncovered a significant association between near-daily cannabis consumption and accelerated, more severe epilepsy trajectories.
Faster Onset of Drug Resistance and Elevated Convulsive Seizures
The investigative team analyzed clinical records from 64 adult patients with drug-resistant epilepsy—defined as persistent seizures despite adequate trials of two or more appropriately chosen antiseizure medications—who were admitted to a specialized inpatient epilepsy monitoring unit (EMU) between 2019 and 2024.
The researchers compared 22 frequent recreational users (defined as using cannabis 20 or more days per month) against 42 nonusers.
A stark contrast emerged across seizure severity and clinical timelines:
- Higher Frequency of Convulsive Events: Frequent users suffered more than twice as many convulsive seizures per year compared to nonusers. Approximately 90% of frequent users experienced generalized tonic-clonic (grand mal) seizures, the type most strongly tied to physical injury and sudden unexpected death in epilepsy (SUDEP), compared to around 50% of nonusers.
- Accelerated Disease Progression: Frequent users reached the inpatient monitoring unit, an indication that standard medications had failed, an average of just 5 years after their first seizure. Nonusers, by comparison, took an average of 18 years to reach the same refractory stage.
- Higher Medication Burden: Despite having lived with epilepsy for far fewer years, frequent cannabis users were discharged on a greater number of concurrent antiseizure medications.
“I was seeing patients with horrible seizures, really severe epilepsy, who didn’t have any of the expected risk factors,” explained senior author Aaron F. Struck, MD, associate professor of neurology at WashU Medicine and the inaugural Endowed Chair in Epilepsy at Barnes-Jewish Hospital. “The one thing they had in common was frequent, high-potency cannabis use. It’s an uncontrolled variable that was appearing more and more in my practice, and nobody had really studied it.”
Distinguishing THC from Antiseizure Cannabinoids
The findings highlight an important pharmacological distinction between purified pharmaceutical cannabinoids and unregulated commercial products. While the U.S. FDA has approved purified cannabidiol (CBD) for certain severe childhood-onset epilepsies, clinical-grade CBD formulations are nonpsychoactive and completely devoid of tetrahydrocannabinol (THC).
In preclinical models, CBD demonstrates anticonvulsant properties, whereas THC—which acts as a partial agonist at cannabinoid CB1 receptors—can exhibit proconvulsant effects under certain physiological conditions. Today’s commercial recreational market is heavily dominated by products characterized by exceptionally high THC concentrations and negligible CBD content.
To address the question of whether patients turned to cannabis as a form of self-medication, researchers evaluated the 15 frequent users with fully documented clinical timelines. All 15 individuals began using cannabis regularly before their first clinical seizure ever occurred, undermining the hypothesis that use was simply a response to preexisting epilepsy.
Functional Circuit Miswiring vs. Physical Scarring
Epilepsy that progresses to such severe drug resistance typically leaves discernible structural damage, such as hippocampal sclerosis. However, the MRI scans of the frequent cannabis users appeared largely normal.
Because cannabinoid CB1 receptors are heavily concentrated in memory and seizure-initiating hubs like the hippocampus, the authors hypothesize that chronic high-dose THC exposure may disrupt the delicate firing dynamics and balance of neural circuits rather than causing overt macrostructural tissue destruction.
The researchers emphasize that the current data demonstrate an observational association rather than direct causation. To resolve whether stopping cannabis use can reverse seizure frequency, the team is designing a prospective, multisite study incorporating objective toxicology assays rather than self-reported usage.
“Right now, the honest answer when a patient asks whether their cannabis use is affecting their seizures is that we’re not sure,” noted first author Santiago Philibert-Rosas, MD. “Larger studies will help us give them a real answer, how much matters and whether stopping helps, so they can make an informed decision.”
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this epilepsy Research:
- Media Contact: Abeeha Shamshad
- Source: WUSTL
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Epilepsia (Sept 22, 2026). “Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy.” Authors: Santiago Philibert-Rosas, Kaitlin A. Guston, Mariel Kalkach-Aparicio, Abigail Keller, Sanaa Semia, Theodore Imhoff-Smith, Cameron J. Brace, Steven E. Haworth, Felipe Branco de Paiva, Dace Almane, Jonathan Williams, Anne Josiah, Bradley Nix, Bruce P. Hermann, Nagesh Adluru, Jana E. Jones, Aaron F. Struck.
- DOI: 10.1002/epi.70456
Abstract
Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy
Objective
Cannabis use has increased substantially, with modern products characterized by high tetrahydrocannabinol concentrations and variable composition. The relationship between frequent cannabis use and epilepsy outcomes remains uncertain. We examined the association between frequent cannabis use and epilepsy severity, clinical phenotype, and imaging characteristics in patients admitted to an epilepsy monitoring unit (EMU).
Methods
This retrospective cohort study included adults with drug-resistant epilepsy admitted to a tertiary care EMU. Patients were classified based on cannabis use documented in the electronic medical record over the year prior to admission. Frequent use was defined as cannabis use on ≥20 days/month; patients with low use were excluded. Primary outcomes included markers of epilepsy severity, including time from epilepsy onset to EMU admission, presence and frequency of focal to bilateral tonic–clonic seizures (FBTCS), and antiseizure medication (ASM) burden. Secondary analyses evaluated epilepsy syndrome and mesial temporal lobe volumetric measures.
Results
Sixty-four patients were included (42 nonusers and 22 frequent users). Frequent cannabis use was associated with shorter time from epilepsy onset to EMU admission (mean [SD] = 5.0 [4.2] vs. 18.1 [16.3] years, p = .004), higher prevalence of FBTCS (90.9% vs. 57.1%, p = .04), greater annualized FBTCS frequency (mean [SD] = 3.00 [3.63] vs. 1.32 [3.87], p = .003), and higher ASM burden (mean [SD] = 3.05 [1.00] vs. 2.21 [1.14], p = .027). All frequent cannabis users had temporal lobe epilepsy (TLE), although the between-group difference in TLE prevalence was not statistically significant. No significant group differences were observed in imaging analysis.
Significance
In this cohort of patients with drug-resistant epilepsy, frequent cannabis use was associated with markers of increased epilepsy severity, including higher FBTCS burden, shorter time to specialized EMU evaluation, and greater ASM requirements. Prospective studies using objective cannabis exposure measures are needed to clarify the relationship between cannabis use and epilepsy outcomes.
